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http://www.biomedcentral.com/1471-2393/13/195RESEARCH ARTICLE Open AccessMaternal adverse effects of different antenatal
magnesium sulphate regimens for improving
maternal and infant outcomes: a systematic
review
Emily S Bain1*, Philippa F Middleton1 and Caroline A Crowther1,2Abstract
Background: Antenatal magnesium sulphate, widely used in obstetrics to improve maternal and infant outcomes,
may be associated with adverse effects for the mother sufficient for treatment cessation. This systematic review
aimed to quantify maternal adverse effects attributed to treatment, assess how adverse effects vary according to
different regimens, and explore women’s experiences with this treatment.
Methods: Bibliographic databases were searched from their inceptions to July 2012 for studies of any design that
reported on maternal adverse effects associated with antenatal magnesium sulphate given to improve maternal or
infant outcomes. Primary outcomes were life-threatening adverse effects of treatment (death, cardiac arrest,
respiratory arrest). For randomised controlled trials, data were meta-analysed, and risk ratios (RR) pooled using
fixed-effects or random-effects models. For non-randomised studies, data were tabulated by design, and
presented as RR, odds ratios or percentages, and summarised narratively.
Results: A total of 143 publications were included (21 randomised trials, 15 non-randomised comparative studies,
32 case series and 75 reports of individual cases), of mixed methodological quality. Compared with placebo or no
treatment, magnesium sulphate was not associated with an increased risk of maternal death, cardiac arrest or
respiratory arrest. Magnesium sulphate significantly increased the risk of ‘any adverse effects’ overall (RR 4.62,
95% CI 2.42-8.83; 4 trials, 13,322 women), and treatment cessation due to adverse effects (RR 2.77; 95% CI 2.32-3.30;
5 trials, 13,666 women). Few subgroup differences were observed (between indications for use and treatment
regimens). In one trial, a lower dose regimen (2 g/3 hours) compared with a higher dose regimen (5 g/4 hours)
significantly reduced treatment cessation (RR 0.05; 95% CI 0.01-0.39, 126 women). Adverse effect estimates from
studies of other designs largely supported data from randomised trials. Case reports supported an association
between iatrogenic overdose of magnesium sulphate and life-threatening consequences.
Conclusions: Appropriate administration of antenatal magnesium sulphate was not shown to be associated with
serious maternal adverse effects, though an increase in ‘minor’ adverse effects and treatment cessation was shown.
Larger trials are needed to determine optimal regimens, achieving maximal effectiveness with minimal adverse effects,
for each antenatal indication for use. Vigilance in the use of magnesium sulphate is essential for women’s safety.
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Magnesium sulphate has a long history of use in obstet-
rics. It is supported as the first line treatment for women
with eclampsia [1-3], and is the drug of choice for women
with severe pre-eclampsia [4]; it has been widely used as a
tocolytic, however, benefit for this indication remains un-
proven [5,6]. Most recently antenatal magnesium sulphate
has been supported for neuroprotection of the fetus,
and it is thus now recommended for women at risk of
very preterm birth [7].
Although life-threatening maternal adverse effects
of magnesium sulphate are considered extremely rare
in obstetrics [8], severe consequences of magnesium
toxicity including respiratory arrest, cardiac arrest and
death have been detailed in case reports. The ‘well
recognised’ and more commonly reported maternal
adverse effects of magnesium sulphate include flush-
ing, increased warmth and sweating due to the per-
ipheral vasodilatory effects of magnesium, and nausea,
vomiting, headaches, muscle weakness, blurred vision,
and intravenous (IV) or intramuscular (IM) site pain
or discomfort [8]. Though such maternal adverse effects
may be considered comparatively ‘minor,’ they have been
associated with the need for early cessation of this ther-
apy, which has benefits when used for maternal and
fetal neuroprotection [4,7].
While maternal adverse effects following antenatal mag-
nesium sulphate administration are well known [4-7,9],
the risk of individual events is unclear, and there has been
a dearth of evidence regarding how such adverse effects
vary by different regimens. Variation in aspects of the
regimens such as the route of administration, dose, and
duration, may help to explain differences in adverse
effects of magnesium sulphate experienced among women
receiving treatment. Although recent evidence suggests
that on average, there are not large differences in the risk
estimates of adverse effects from randomised controlled
trials and observational studies [10], some uncertainty
remains regarding the consistency of estimates provided
by diverse study designs [11].
In view of the extremely widespread use of antenatal
magnesium sulphate in obstetric practice, in this system-
atic review we aimed to quantify the extent of maternal ad-
verse effects attributed to treatment, explore any variation
in risk estimates between study designs, and to assess how
such maternal adverse effects vary according to different
regimens for administration and different indications
for use. Implementation of this therapy may be strength-
ened, and the safety improved, if guidelines and recom-
mendations for practice can be based on such knowledge.
As it is known that maternal adverse effects may affect
adherence and therapy cessation, we additionally aimed
to explore and better understand women’s responses to
their experiences with this therapy.Methods
Search strategy
Additional file 1 provides the PRISMA checklist. A compre-
hensive search of the bibliographic databases, MEDLINE,
Embase, CENTRAL (Cochrane Central Register of Con-
trolled Trials) and TOXLINE, was undertaken from their
respective inceptions to July 2012, using a combination of
MeSH and free text terms [12]. The search strategies used
are given in Additional file 2. No date or language restric-
tions were applied, however, because of logistical con-
straints, for non-English papers only those with an available
partial/full translation were retrieved. Conference Proceed-
ing Citation Index-Science, OpenSIGLE, ClinicalTrials.gov,
Current Controlled Trials metaRegister of Controlled
Trials, International Clinical Trials Registry, and Google
were additionally searched using key word searches (includ-
ing to identify any publically available incident reports
from patient safety organisations). The reference lists
of any eligible articles identified were checked for
additional references. The blog search engine blogsearch.
google.com and the search engine Google, limited to
Discussions, were searched using key words ([“magnesium
sulfate” OR “magnesium sulphate”] AND pregnancy)
(sorted by relevance). Because of logistical constraints, it
was pre-specified that sampling would cease once 20 rele-
vant blogs and 10 relevant discussion forum threads were
identified, with up to a total of five relevant threads from
each original site sampled, if available.
Inclusion criteria
Studies
We included intervention (randomised, cluster-randomised,
quasi-randomised and non-randomised comparative stud-
ies) and observational studies (cohort, case-control, cross-
sectional, case series and case reports). We included studies
available as abstracts only, along with full-text publica-
tions. Personal blogs and discussion forum threads from
pregnancy-related internet sites were included, along
with incident reports from patient safety organisations.
Participants, interventions and comparisons
We included women given antenatal magnesium sulphate:
for pre-eclampsia/eclampsia (including when it was
continued/initiated in the immediate postpartum period);
for tocolysis to women in preterm labour or who had had
at least one episode of threatened preterm labour; for
neuroprotection of the fetus, to women considered at risk
of preterm birth (less than 37 weeks’ gestation), or at term,
regardless of the regimen for administration (including
iatrogenic overdoses). We excluded studies where women
were given oral magnesium sulphate, and where magne-
sium sulphate was given as an adjuvant during anaesthesia,
or where magnesium sulphate was given in combination
with another agent for tocolysis. We included instances
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placebo or to a different magnesium sulphate regimen,
and/or, where the study’s exposure was magnesium
sulphate. We excluded studies where magnesium sulphate
was compared to an alternative therapy.
Outcomes
We included studies that reported data on maternal
adverse effects associated with magnesium sulphate.
Primary outcomes were life-threatening adverse effects
of treatment (death, cardiac arrest, respiratory arrest).
Secondary outcomes included other maternal-reported
or clinical maternal adverse effects attributed to treat-
ment (e.g. warmth and flushing, arm discomfort), out-
comes associated with interventions to reduce potential/
actual adverse effects (e.g. use of calcium gluconate,
discontinuation of treatment), and other outcomes of
interest (including caesarean section, pulmonary oedema,
and postpartum haemorrhage). We used the definitions
as used by the study authors.
Study selection
After screening all titles and abstracts, we obtained the full-
text article for any study which appeared to meet the inclu-
sion criteria based on the title and/or abstract, along with
any reviews that may have provided relevant references. All
full-text articles and abstracts were assessed for inclusion.
Each stage was carried out by one reviewer (ESB) with the
second reviewer (PFM) assessing a random sample (10% of
the total). We resolved any discrepancies through discus-
sion, or if required, we consulted the third reviewer (CAC).
Data extraction and management
Once a study was included, data were extracted using a
standardised form. Data extracted included information re-
garding study design, participants, the magnesium sulphate
regimen(s), the control/comparison if applicable, maternal
adverse effects reported and results relevant to the review,
the risk of bias, confounding and relevance. For personal
blogs and discussion forum threads, information regar-
ding perceived purpose and/or benefits of treatment, and
women’s experiences with treatment, particularly consider-
ing adverse effects were extracted. Extraction was carried
out by one reviewer (ESB), with the second reviewer
(PFM) independently extracting a random sample (10% of
the total, and all included randomised controlled trials).
We resolved any discrepancies through discussion, or if
required, we consulted the third reviewer (CAC).
Assessment of study quality/ risk of bias
Quality appraisal of intervention studies was undertaken
utilising established guidelines provided in the Cochrane
Handbook for Systematic Reviews of Interventions [13].
The quality assessment of observational studies was guidedby recommendations from the Cochrane Handbook on
assessing the quality of non-randomised studies [13] (which
highlights that attention must be paid particularly to
selection bias) and principles of the Newcastle-Ottawa
Scale [14], where we judged the quality of each study on
three main aspects: the selection of the study groups; the
comparability of the groups; and the ascertainment of ei-
ther the exposure of outcome of interest for case-control
or cohort studies respectively; for case series we primarily
considered selection of the study group. As it has been
suggested that the quality of adverse effect detection and
reporting is not always adequately assessed, it was also im-
portant to consider the methods used to detect adverse ef-
fects and how rigorous these methods were, along with an
assessment of incomplete reporting [12,15].
Data synthesis and analysis
The analysis and presentation of results were categorised
by study design. Statistical analyses were performed using
Review Manager, version 5.1 (The Cochrane Collabor-
ation, Copenhagen, Denmark).
For intervention studies we presented quantitative data
from individual studies where possible as risk ratios (RR)
with 95% confidence intervals (CI) for dichotomous
outcomes. For all outcomes, we carried out analyses as
far as possible on an intention-to-treat basis. Pooled esti-
mates (summary RR with 95% CI) were calculated using
fixed-effect meta-analysis (Mantel-Haenszel method) where
there was a sufficient quantity of data, with clinical homo-
geneity. Where we considered that there was clinical
heterogeneity sufficient to expect the underlying effects dif-
fered between trials, or there was substantial statistical het-
erogeneity (where I2 was greater than 30% and either T2
was greater than zero, or there was a low P-value (less than
0.10) in the Chi2 test), summary estimates were calculated
using random-effects meta-analysis.
Separate comparisons were performed for those studies
assessing magnesium sulphate versus no treatment/pla-
cebo, and those comparing different magnesium sulphate
regimens. For all review outcomes, we conducted subgroup
analyses based on indication for use (i.e. given for pre-
eclampsia/eclampsia; fetal neuroprotection; tocolysis), as
this was considered likely to influence outcomes. Add-
itional subgroup analyses were planned if sufficient data
were available based on aspects of the magnesium sulphate
regimen (i.e. route of administration; dose). We assessed
subgroup differences by interaction tests available within
Review Manager, and where applicable, we have quoted
the Chi2 statistic and P-value, and the interaction test I2
value. We included only primary outcomes and the out-
comes: discontinuation due to adverse effects, calcium glu-
conate use, and ‘any adverse effects’ in subgroup analyses.
For observational studies (cohort, case-control, cross-
sectional, case series) we presented effect estimates where
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CIs, adjusted RR or OR if reported with 95% CIs, or
P-values only, in tabular format based on study type; we
used narrative synthesis to summarise the studies. Data
from case reports were tabulated and subsequently grouped
according to themes. For personal blogs and discussion
forum threads, relevant text was tabulated (considering per-
ceived purpose/benefits of magnesium sulphate and experi-
ence of magnesium sulphate therapy, before, during and
after treatment), and thematic analysis techniques were
used to identify and summarise emerging themes.Results
Study selection
The results of the search strategy, including the
sources of the studies, culling and final inclusion ofFigure 1 Flow diagram of included studies. *Numbers indicate level of evid
Research Council (NHMRC) Evidence Hierarchy Available at: https://www.nhmrc
evidence_120423.pdf.studies are shown in Figure 1. The initial database
searching identified 5,062 articles. Review of the
abstracts/titles and exclusion of irrelevant/duplicate
articles yielded 1,034 articles. Of these articles, we
excluded 896 for the documented reasons. We there-
fore included 138 studies, along with an additional
five studies identified through other searching; a
total of 143 studies (see Additional file 3 for Refer-
ences to all included reports). In the case of multiple
publications from the same study, we included the
report with the most relevant data relating to
adverse effects.Evidence from randomised controlled trials
Twenty one randomised trials (16,812 women) were
included, the characteristics of which are detailed inence, according to Australian Government National Health and Medical
.gov.au/_files_nhmrc/file/guidelines/developers/nhmrc_levels_grades_
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in Figures 2, 3 and 4. The trials assessed a variety of differ-
ent treatment regimens with varying comparators, and
are therefore assessed under six different comparisons:
1. Magnesium sulphate versus placebo or no treatment
(11 trials).
2. Lower dose versus higher dose magnesium sulphate
IM maintenance (2 trials).
3. Magnesium sulphate IV maintenance versus IM
maintenance (3 trials).
4. Short versus standard (24 hour) postpartum
magnesium sulphate maintenance (2 trials).
5. Lower dose versus higher dose magnesium sulphate
IV maintenance (2 trials).
6. ‘Ready-to-use’ magnesium sulphate solution versus a
reference drug requiring dilution (1 trial).
Considering the risk of bias for trials in Comparison 1
(magnesium sulphate versus placebo or no treatment),
sequence generation and allocation concealment were
adequate in the majority of trials (6/11 and 8/11 trials
respectively) (Figure 2). For other trials, it was unclear
whether this was adequate, and for one trial, allocation
concealment was not considered adequate. For six trials,
blinding of personnel, women and outcome assessors
was considered adequate, whilst for four trials this was
not considered adequate, and for one trial this was
unclear. The randomised trials in Comparisons 2-6
(different magnesium sulphate regimens) were considered
at a comparatively higher risk of bias overall (Figure 3).
For the majority of trials, it was unclear whether sequence
generation and allocation concealment were adequate
(5/10 and 8/10 trials respectively). Blinding of personnel
and women was not possible in any of the trials; none
of the trials reported that outcomes were assessed in a
blinded manner.
Comparison 1: magnesium sulphate versus placebo or
no treatment
This comparison included 11 trials with 15,709 women
[16-26]. In six trials, the indication for use of magnesiumFigure 2 Risk of bias for randomised controlled trials (Comparison 1).
risk of bias item presented as percentages across included studies from Cosulphate was the prevention or treatment of eclampsia;
for three trials, the indication was fetal neuroprotection,
and for two trials, the prevention of preterm birth (see
Table 1 and Additional file 5 for effect estimates and forest
plots for outcomes in Comparison 1).
Life-threatening adverse effects of treatment
No significant differences were seen between magnesium
sulphate and placebo/no treatment for maternal death
(RR 0.53; 95% CI 0.26 to 1.09; 5 trials, 14,662 women;
Analysis 1.1), cardiac arrest (RR 0.80; 95% CI 0.21 to
2.98; 4 trials, 13,977 women; Analysis 1.2) or respiratory
arrest (RR 2.50; 95% CI 0.49 to 12.88; 4 trials 13,977
women; Analysis 1.3).
Interventions to limit adverse effects
Women receiving magnesium sulphate experienced a
significantly increased (almost three times) risk of dis-
continuing treatment due to associated adverse effects
(RR 2.77; 95% CI 2.32 to 3.30; 5 trials 13,666 women;
Analysis 1.4). There were no significant differences
between groups in the outcomes calcium gluconate
administration (RR 1.35; 95% CI 0.63 to 2.88; 2 trials,
10,795 women; Analysis 1.5) and intensive care unit ad-
mission (RR 0.97; 95% CI 0.72 to 1.30; 2 trials, 11,172
women; Analysis 1.6).
Adverse effects associated with treatment
Women receiving magnesium sulphate were almost
five times more likely to experience ‘any side effects’ in
the four included trials (RR 4.62; 95% CI 2.42 to 8.83;
13,322 women; Analysis 1.7). Women receiving mag-
nesium sulphate compared with women receiving no
treatment/placebo experienced an approximately 50%
increased risk of hypotension (RR 1.52; 95% CI 1.10 to
2.11; 3 trials, 1,782 women; Analysis 1.11) and tachycar-
dia (RR 1.53; 95% CI 1.03 to 2.29; 1 trial, 1,062 women;
Analysis 1.12). Compared with women receiving no
treatment/placebo, women receiving magnesium sulphate
experienced an approximately 50% increased risk of
problems at the IM injection site (RR 1.49; 95% CI 1.25
to 1.79; 1 trial, 4,553 women; Analysis 1.25), and moreRisk of bias graph showing review authors’ judgements about each
mparison 1.
Figure 3 Risk of bias for randomised controlled trials (Comparisons 2–6). Risk of bias graph showing review authors’ judgements about
each risk of bias item presented as percentages across included studies from Comparisons 2–6.
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IV site (RR 6.34; 95% CI 3.10 to 12.98; 3 trials, 8,704
women; Analysis 1.24).
Women receiving magnesium sulphate had an approxi-
mately 50% increased risk of respiratory depression
(RR 1.41; 95% CI 1.07 to 1.86; 5 trials, 14,098 women;
Analysis 1.8), more than two times the risk of drowsiness/
confusion (RR 2.46; 95% CI 1.83 to 3.29; 3 trials, 11,189
women; Analysis 1.16), headache (RR 2.21; 95% CI 1.27 to
3.86; 2 trials, 10,556 women; Analysis 1.17), dizziness (RR
2.62; 95% CI 1.63 to 4.21; 2 trials, 11,054 women; Analysis
1.19), mouth dryness or thirst (RR 2.38; 95% CI 1.59 to
3.56; 2 trials, 11,054 women; Analysis 1.18) and blurred
vision (RR 2.34; 95% CI 1.32 to 4.14; 1 trial, 1,062
women; Analysis 1.22), more than five times the risk of
nausea and/or vomiting (RR 5.50; 95% CI 2.29 to 13.22;
4 trials; 13,821 women; Analysis 1.14), nearly seven
times the risk of flushing and warmth (RR 6.94; 95% CI
4.19 to 11.49; 5 trials, 13,956 women; Analysis 1.13) and
sweating (RR 6.37; 95% CI 1.96 to 20.65; 2 trials, 3,265
women; Analysis 1.20), nearly 15 times the risk of itching
and tingling (RR 14.98; 95% CI 1.98 to 113.38; 1 trial,
9,992 women; Analysis 1.21), and more than 15 times
the risk of muscle weakness (RR 15.81; 95% CI 7.36 to
33.96; 3 trials, 10,212 women; Analysis 1.15).
There were no significant differences between groups
for the outcomes absent/reduced tendon reflexes (RR
1.01; 95% CI 0.71 to 1.44; 3 trials; 11,241 women; Ana-
lysis 1.9) and slurred speech (RR 3.04; 95% CI 0.13 to
73.42; 1 trial, 135 women; Analysis 1.23).Other outcomes
For women receiving magnesium sulphate compared to
no treatment/placebo, a small significant increased risk
of caesarean section was shown (RR 1.04; 95% CI 1.00
to 1.08; 10 trials, 14,105 women; Analysis 1.26). No dif-
ferences were seen between groups for the outcomes
postpartum haemorrhage (RR 0.94; 95% CI 0.87 to 1.04;
4 trials, 10,535 women; Analysis 1.27) and pulmonary
oedema (RR 1.12; 95% CI 0.72 to 1.74; 4 trials, 12,787
women; Analysis 1.28).Subgroup analysis by indication for use
When considering indication for use, the subgroup
interaction tests for the majority of outcomes were non-
significant, indicating no differential effects according
to the different reasons for administration (see Table 1
for effect estimates for indication for use subgroups and
Additional file 5 for forest plots). While substantial
statistical heterogeneity (I2 > 90%) was observed for the
outcomes ‘any side effects’, flushing and/or warmth and
nausea and/or vomiting, this could not be explained by
considering the indication for use of treatment. In each
case the test for subgroup differences was non-significant
(‘any side effects’: Chi2 = 1.68, P = 0.43, I2 = 0%; Analysis
1.7) (flushing and/or warmth: Chi2 = 0.07, P = 0.79,
I2 = 0%; Analysis 1.13) (nausea and/or vomiting: Chi2 =
1.16, P = 0.28, I2 = 13.9%; Analysis 1.14).
For the outcome problems at the IV site and/or arm
discomfort, the subgroup interaction test indicated a sig-
nificant difference between indication for use subgroups,
and a possible differential effect in favour of receiving
treatment for pre-eclampsia, with women receiving treat-
ment for fetal neuroprotection being more likely to
experience arm discomfort (Chi2 = 25.80, P = < 0.00001,
I2 = 96.1%; Analysis 1.24). It is possible, however, that the
methods used to collect information on arm discomfort/
problems at the IV site differed substantially between
trials, and could help to explain this observed differen-
tial effect.
Subgroup analysis by regimen for administration
To explore the effect of aspects of the regimen for
administration of magnesium sulphate on adverse effects,
the trials from Comparison 1 were grouped as pre-
specified where possible according to their dosage
and/or route of administration (loading dose only; loading
plus maintenance dose; 4 g IV loading dose plus any
maintenance; 5-6 g IV loading dose plus any maintenance;
1 g/hour IV maintenance; 2-3 g/hour IV maintenance; IM
maintenance).
For the outcomes maternal death, cardiac arrest, re-
spiratory arrest and use of calcium gluconate, no signifi-
cant differences were shown between the magnesium
Figure 4 Risk of bias for randomised controlled trials
(Comparisons 1–6). Risk of bias summary showing review authors’
judgements about each risk of bias item for included studies from
Comparisons 1–6. Each risk of bias item is judged as at a low risk of
bias, unclear risk of bias or high risk of bias.
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the subgroups, and the subgroup interaction tests for all
outcomes indicated no significant differential effects
across the treatment subgroups (see Table 1 for effect
estimates for regimen subgroups and Additional file 5
for forest plots). The significantly increased risk of dis-
continuing treatment due to adverse effects and experi-
encing ‘any side effects’ for the magnesium sulphate
group was seen across all of the different regimen sub-
groups (see Analyses 1.4 and 1.7); for both outcomes,
the subgroup interaction tests did not indicate differen-
tial effects according to the subgroups.
Comparison 2: lower dose versus higher dose IM
maintenance: prevention or treatment of eclampsia
This comparison included two trials with 176 women with
both trials assessing magnesium sulphate for eclampsia, or
‘imminent eclampsia’ (see Table 2 and Additional file 5
for effect estimates and forest plots for Comparison 2).
One trial compared a lower dose ‘Dhaka’ regimen from
Bangladesh: 4 g IV and 6 g IM as a loading dose, and
2.5 g IM every four hours as maintenance, with a higher
dose ‘Bhalla’ regimen: 4 g IV and 8 g IM as a loading
dose, and 4 g IM every four hours as maintenance [27].
The second trial compared a loading dose of 4 g IV, and
2 g IM every three hours as maintenance, with Pritchard’s
regimen (a loading dose of 4 g IV and 10 g IM, and 5 g IM
every four hours as maintenance) [28].
Life-threatening adverse effects of treatment
No significant difference between groups was shown for
the risk of ‘maternal death due to toxicity’ in one trial of
126 women (RR 0.25, 95% CI 0.01 to 6.05; Analysis 2.1).
No other primary review outcomes were reported.
Interventions to limit adverse effects
Women allocated to the lower dose regimen were sig-
nificantly less likely to have treatment stopped due to
‘toxicity’ in one trial, an approximate 95% relative risk
reduction (RR 0.05; 95% 0.01 to 0.39; 126 women; Ana-
lysis 2.2). Women allocated to the lower dose regimen
were significantly less likely to have a maintenance dose
deferred or skipped due to adverse effects, an approxi-
mate 64% relative risk reduction (RR 0.36; 95% CI 0.20
to 0.63; 2 trials, 176 women; Analysis 2.3). No clear dif-
ference was shown for the need for calcium gluconate
in one trial (RR 0.25; 95% CI 0.06 to 1.06; 1 trial, 50
women; Analysis 2.4).
Table 1 Adverse effect estimates from randomised controlled trials (Comparison 1)
Outcome or subgroup Studies Participants Method (I2(%))* RR (95% CI)
Comparison 1: Magnesium sulphate versus placebo or no treatment
1.1 Death 5 [17,19,20,23,25] 14662 F (0) 0.53 (0.26, 1.09)
1.1.1 Treatment of pre-eclampsia/eclampsia 2 [17,20] 10795 F (0) 0.53 (0.26, 1.09)
1.1.2 Fetal neuroprotection 3 [19,23,25] 3867 F (NA) No deaths
1.1.3 LD only 1 [23] 564 F (NA) No deaths
1.1.4 LD and MD 4 [17,19,20,25] 14098 F (0) 0.53 (0.26, 1.09)
1.1.5 4 g IV LD and MD 3 [17,19,20] 11857 F (0) 0.53 (0.26, 1.09)
1.1.6 5–6 g IV LD and MD 1 [25] 2241 F (NA) No deaths
1.1.7 1 g/hour IV MD 3 [17,19,20] 7264 F (0) 0.41 (0.12, 1.43)
1.1.8 2–3 g/hour IV MD 1 [25] 2241 F (NA) No deaths
1.1.9 IM MD 1 [20] 4593 F (NA) 0.61 (0.25, 1.48)
1.2 Cardiac arrest 4 [19,20,23,25] 13977 F (NA) 0.80 (0.21, 2.98)
1.2.1 Treatment of pre-eclampsia/eclampsia 1 [20] 10110 F (NA) 0.80 (0.21, 2.98)
1.2.2 Fetal neuroprotection 3 [19,23,25] 3867 F (NA) No cardiac arrests
1.2.3 LD only 1 [23] 564 F (NA) No cardiac arrests
1.2.4 LD and MD 3 [19,20,25] 13413 F (NA) 0.80 (0.21, 2.98)
1.3 Respiratory arrest 4 [19,20,23,25] 13977 F (NA) 2.50 (0.49, 12.88)
1.3.1 Treatment of pre-eclampsia/eclampsia 1 [20] 10110 F (NA) 2.50 (0.49, 12.88)
1.3.2 Fetal neuroprotection 3 [19,23,25] 3867 F (NA) No respiratory arrests
1.3.3 LD only 1 [23] 564 F (NA) No respiratory arrests
1.3.4 LD and MD 3 [19,20,25] 13413 F (NA) 2.50 (0.49, 12.88)
1.4 Discontinuation due to adverse effects 5 [18-20,25,26] 13666 F (0) 2.77 (2.32, 3.30)
1.4.1 Treatment of pre-eclampsia/eclampsia 2 [20,26] 10245 F (0) 2.69 (2.18, 3.31)
1.4.2 Fetal neuroprotection 2 [19,25] 3265 F (0) 2.81 (2.01, 3.93)
1.4.3 Tocolysis 1 [18] 156 F (NA) 17.88 (1.05, 304.57)
1.4.4 LD and MD 5 [18-20,25,26] 13666 F (0) 2.77 (2.32, 3.30)
1.4.5 4 g IV LD and MD 3 [18-20] 11328 F (0) 2.75 (2.28, 3.31)
1.4.6 5–6 g IV LD and MD 2 [25,26] 2338 F (0) 2.94 (1.69, 5.12)
1.4.7 1 g/hour IV MD 1 [19] 1062 F (NA) 2.74 (1.81, 4.15)
1.4.8 2–3 g/hour IV MD 3 [18,25,26] 2494 F (0) 3.38 (1.97, 5.78)
1.5 Given calcium gluconate
1.5.1 Treatment of pre-eclampsia/eclampsia 2 [17,20] 10795 F (0) 1.35 (0.63, 2.88)
1.5.2 4 g IV LD and MD 2 [17,20] 10795 F (0) 1.35 (0.63, 2.88)
1.6 Intensive care unit admission 2 [19,20] 11172 F (NA) 0.97 (0.72, 1.30)
1.6.1 Treatment of pre-eclampsia/eclampsia 1 [20] 10110 F (NA) 0.97 (0.72, 1.30)
1.6.2 Fetal neuroprotection 1 [19] 1062 F (NA) No admissions
1.7 Any side effects 4 [19,20,22,25] 13322 R (98) 4.62 (2.42, 8.83)
1.7.1 Treatment of pre-eclampsia/eclampsia 1 [20] 9992 F (NA) 5.26 (4.59, 6.03)
1.7.2 Fetal neuroprotection 2 [19,25] 3265 R (98) 3.82 (1.38, 10.59)
1.7.3 Tocolysis 1 [22] 65 F (NA) 26.71 (1.64, 435.03)
1.7.4 LD and MD 4 [19,20,22,25] 13322 R (98) 4.62 (2.42, 8.83)
1.7.5 4 g IV LD and MD 2 [19,20] 11054 R (99) 3.52 (1.49, 8.32)
1.7.6 5–6 g IV LD and MD 2 [22,25] 2268 F (5) 6.28 (5.36, 7.35)
1.7.7 1 g /hour IV MD 2 [19,20] 6501 R (98) 3.31 (1.59, 6.88)
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Table 1 Adverse effect estimates from randomised controlled trials (Comparison 1) (Continued)
1.7.8 2–3 g/hour IV MD 2 [22,25] 2268 F (5) 6.28 (5.36, 7.35)
1.7.9 IM MD 1 [20] 4553 F (NA) 5.84 (4.80, 7.09)
1.8 Respiratory depression/other respiratory problems 5[17-20,25] 14098 F (29) 1.41 (1.07, 1.86)
1.8.1 Treatment of pre-eclampsia/eclampsia 2 [17,20] 10677 F (0) 1.98 (1.24, 3.15)
1.8.2 Fetal neuroprotection 2 [19,25] 3265 F (29) 1.12 (0.79, 1.59)
1.8.3 Tocolysis 1 [18] 156 F (NA) 3.16 (0.13, 76.30)
1.9 Absent or reduced tendon reflexes 3 [17,20,23] 11241 F (0) 1.01 (0.71, 1.44)
1.9.1 Treatment of pre-eclampsia/eclampsia 2 [17,20] 10677 F (0) 1.00 (0.70, 1.42)
1.9.2 Fetal neuroprotection 1 [23] 564 F (NA) 1.94 (0.18, 21.32)
1.10 Respiratory depression and absent reflexes
1.10.1 Treatment of pre-eclampsia/eclampsia 3 [17,20,21] 10899 F (0) 5.96 (0.72, 49.40)
1.11 Hypotension 3 [18,19,23] 1782 F (0) 1.52 (1.10, 2.11)
1.11.1 Fetal neuroprotection 2 [19,23] 1626 F (0) 1.51 (1.09, 2.09)
1.11.2 Tocolysis 1 [18] 156 F (NA) 3.16 (0.13, 76.30)
1.12 Tachycardia
1.12.1 Fetal neuroprotection 1 [19] 1062 F (NA) 1.53 (1.03, 2.29)
1.13 Flushing and/or warmth 5 [19,20,23,25,26] 13956 R (92) 6.94 (4.19, 11.49)
1.13.1 Treatment of pre-eclampsia/eclampsia 2 [20,26] 10127 R (91) 6.39 (2.44, 16.74)
1.13.2 Fetal neuroprotection 3 [19,23,25] 3829 R (94) 7.55 (3.39, 16.85)
1.14 Nausea and/or vomiting 4 [19,20,23,25] 13821 R (92) 5.50 (2.29, 13.22)
1.14.1 Treatment of pre-eclampsia/eclampsia 1 [20] 9992 F (NA) 8.88 (5.46, 14.43)
1.14.2 Fetal neuroprotection 3 [19,23,25] 3829 R (92) 4.60 (1.54, 13.73)
1.15 Muscle weakness 3 [16,18,20] 10212 F (0) 15.81 (7.36, 33.96)
1.15.1 Treatment of pre-eclampsia/eclampsia 2 [16,20] 10056 F (0) 15.97 (7.23, 35.30)
1.15.2 Tocolysis 1 [18] 156 F (NA) 13.68 (0.78, 238.67)
1.16 Drowsiness or confusion 3 [19,20,26] 11189 F (0) 2.46 (1.83, 3.29)
1.16.1 Treatment of pre-eclampsia/eclampsia 2 [20,26] 10127 F (0) 2.26 (1.06, 4.85)
1.16.2 Fetal neuroprotection 1 [19] 1062 F (NA) 2.49 (1.82, 3.42)
1.17 Headache 2 [20,23] 10556 F (0) 2.21 (1.27, 3.86)
1.17.1 Treatment of pre-eclampsia/eclampsia 1 [20] 9992 F (NA) 2.12 (1.19, 3.76)
1.17.2 Fetal neuroprotection 1 [23] 564 F (NA) 3.89 (0.44, 34.57)
1.18 Thirst or mouth dryness 2 [19,20] 11054 R (42) 2.38 (1.59, 3.56)
1.18.1 Treatment of pre-eclampsia/eclampsia 1 [20] 9992 F (NA) 3.36 (1.72, 6.58)
1.18.2 Fetal neuroprotection 1 [19] 1062 F (NA) 2.11 (1.72, 2.59)
1.19 Dizziness 2 [19,20] 11054 R (39) 2.62 (1.63, 4.21)
1.19.1 Treatment of pre-eclampsia/eclampsia 1 [20] 9992 F (NA) 3.70 (1.84, 7.42)
1.19.2 Fetal neuroprotection 1 [19] 1062 F (NA) 2.21 (1.53, 3.19)
1.20 Sweating
1.20.1 Fetal neuroprotection 2 [19,25] 3265 R (95) 6.37 (1.96, 20.65)
1.21 Itching and/or tingling
1.21.1 Treatment of pre-eclampsia/eclampsia 1 [20] 9992 F (NA) 14.98 (1.98, 113.38)
1.22 Blurred vision
1.22.1 Fetal neuroprotection 1 [19] 1062 F (NA) 2.34 (1.32, 4.14)
1.23 Slurred speech
1.23.1 Treatment of pre-eclampsia/eclampsia 1 [26] 135 F (NA) 3.04 (0.13, 73.42)
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Table 1 Adverse effect estimates from randomised controlled trials (Comparison 1) (Continued)
1.24 Problems at the IV site or arm discomfort 3 [19,20,25] 8704 R (92) 6.34 (3.10, 12.98)
1.24.1 Treatment of pre-eclampsia/eclampsia 1 [20] 5439 F (NA) 3.05 (2.15, 4.32)
1.24.2 Fetal neuroprotection 2 [19,25] 3265 F (NA) 9.11 (7.18, 11.55)
1.25 Problems at the IM site
1.25.1 Treatment of pre-eclampsia/eclampsia 1 [20] 4553 F (NA) 1.49 (1.25, 1.79)
1.26 Caesarean section 10 [16-21,23-26] 14105 F (0) 1.04 (1.00, 1.08)
1.26.1 Treatment of pre-eclampsia/eclampsia 6 [16,17,20-22,26] 10096 F (0) 1.05 (1.01, 1.10)
1.26.2 Fetal neuroprotection 3 [19,23,25] 3853 F (19) 1.00 (0.93, 1.08)
1.26.3 Tocolysis 1 [18] 156 F (NA) 0.90 (0.45, 1.82)
1.27 Postpartum haemorrhage 4 [19,20,23,26] 10535 F (0) 0.94 (0.87, 1.04)
1.27.1 Treatment of pre-eclampsia/eclampsia 2 [20,26] 8909 R (43) 1.31 (0.39, 4.41)
1.27.2 Fetal neuroprotection 2 [19,23] 1626 F (0) 0.84 (0.61, 1.15)
1.28 Pulmonary oedema 4 [20,21,24,25] 12787 F (8) 1.12 (0.72, 1.74)
1.28.1 Treatment of pre-eclampsia/eclampsia 3 [20,21,24] 10560 F (0) 0.95 (0.60, 1.57)
1.28.2 Fetal neuroprotection 1 [25] 2227 F (NA) 2.80 (0.75, 10.53)
I2 statistics is a test of heterogeneity; where I2 was > 30% summary estimates were calculated using random-effects meta-analysis; the bold effect estimates
indicate statistical significance.
Abbreviations: CI confidence interval, F fixed-effect, g gram, IM intramuscular, IV intravenous, LD loading dose, MD maintenance dose, NA not applicable,
R random-effects, RR risk ratio.
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Women allocated to the lower dose regimen were
significantly less likely to have absent tendon reflexes
during treatment, an approximate 79% relative risk
reduction (RR 0.21; 95% CI 0.10 to 0.46; 2 trials, 176
women; Analysis 2.6). There were insufficient data for reli-
able conclusions about the differential effects on respira-
tory depression in one trial of 126 women (RR 0.25;
95% CI 0.01 to 6.05; Analysis 2.5). There were no cases
of gluteal abscess in one trial of 126 women measuring
this outcome (Analysis 2.7).
Other outcomes
No significant differences were shown between groups
in one trial of 126 women for the outcomes postpartum
haemorrhage (RR 0.38; 95% CI 0.03 to 4.03; Analysis 2.8)
and pulmonary oedema (RR 0.25; 95% CI 0.01 to 6.05;
Analysis 2.9).
Comparison 3: IV maintenance versus IM maintenance:
prevention or treatment of eclampsia
This comparison included three trials with 361 women
(see Table 2 and Additional file 5 for effect estimates
and forest plots for Comparison 3); all trials assessed
magnesium sulphate for the prevention or treatment of
eclampsia. Two trials compared Pritchard’s IM regimen
(a loading dose of 4 g IV and 10 g IM (5 g in each but-
tock), and 5 g IM in alternative buttocks every four
hours as maintenance) with either a loading dose of 6 g
IV, and 2 g/hour IV maintenance [30], or a loading dose
of 4 g IV, and 0.75 g/hour IV maintenance [29]. The thirdtrial did not describe its regimens, and compared the use
of an IV Springfusor pump with standard hospital practice
(IV loading dose; IM maintenance) [31].
Life-threatening adverse effects of treatment
In one trial, no significant difference was seen for the
outcome maternal death (RR 0.35, 95% CI 0.04 to 3.27;
1 trial, 137 women; Analysis 3.1). There were no data on
the other primary outcomes.
Interventions to limit adverse effects
No clear difference was seen for the outcome discon-
tinuation or modification of treatment due to adverse
effects (RR 1.46, 95% CI 0.83 to 2.58; 2 trials, 317 women;
Analysis 3.2).
Adverse effects associated with treatment
No significant difference was seen in two trials for the
outcome ‘clinical signs of toxicity’ (RR 0.82; 95% CI 0.05
to 12.56; 154 women; Analysis 3.3). In one trial of 300
women, women allocated to the IV regimen were almost
five times more likely to report their pain level as ‘ac-
ceptable,’ compared with women allocated to the IM
regimen (RR 4.93; 95% CI 3.56 to 6.78; Analysis 3.4).
Other outcomes
There were insufficient data for reliable conclusions about
the differential effects on caesarean section (RR 1.03;
95% CI 0.78 to 1.35; 2 trials, 154 women; Analysis 3.5)
and postpartum haemorrhage (RR 0.35; 95% CI 0.04 to
3.27; 1 trial, 137 women; Analysis 3.6).
Table 2 Adverse effect estimates from randomised controlled trials (Comparisons 2–4)
Outcome or subgroup Studies Participants Method (I2(%))* RR (95% CI)
Comparison 2: lower dose versus higher dose magnesium sulphate IM maintenance: treatment of pre-eclampsia/eclampsia
2.1 Death due to ‘toxicity’
2.1.1 4 g IV LD; 2 g/3 h IM MD versus Pritchard’s regimen^ 1 [28] 126 F (NA) 0.25 (0.01, 6.05)
2.2 Stopped due to ‘toxicity’
2.2.1 4 g IV LD; 2 g/3 h IM MD versus Pritchard’s regimen^ 1 [28] 126 F (NA) 0.05 (0.01, 0.39)
2.3 Deferred or skipped doses 2 [27,28] 176 F (0) 0.36 (0.20, 0.63)
2.3.1 4 g IV LD; 2 g/3 h IM MD versus Pritchard’s regimen^ 1 [28] 126 F (NA) 0.43 (0.23, 0.83)
2.3.2 ‘Dhaka’ regimen* versus ‘Bhalla’ regimen~ 1 [27] 50 F (NA) 0.23 (0.07, 0.71)
2.4 Given calcium gluconate
2.4.1 ‘Dhaka’ regimen* versus ‘Bhalla’ regimen~ 1 [27] 50 F (NA) 0.25 (0.60, 1.06)
2.5 Respiratory depression
2.5.1 4 g IV LD; 2 g/3 h IM MD versus Pritchard’s regimen^ 1 [28] 126 F (NA) 0.25 (0.01, 6.05)
2.6 Absent tendon reflexes 2 [27,28] 176 F (0) 0.21 (0.10, 0.46)
2.6.1 4 g IV LD; 2 g/3 h IM MD versus Pritchard’s regimen^ 1 [28] 126 F (NA) 0.20 (0.08, 0.50)
2.6.2 ‘Dhaka’ regimen* versus ‘Bhalla’ regimen~ 1 [27] 50 F (NA) 0.25 (0.06, 1.06)
2.7 Gluteal abscess (pain, phlebitis, inflammation)
2.7.1 4 g IV LD; 2 g/3 h IM MD versus Pritchard’s regimen^ 1 [28] 126 F (NA) No gluteal abscesses
2.8 Postpartum haemorrhage
2.8.1 4 g IV LD; 2 g/3 h IM MD versus Pritchard’s regimen^ 1 [28] 126 F (NA) 0.38 (0.03, 4.03)
2.9 Pulmonary oedema
2.9.1 4 g IV LD; 2 g/3 h IM MD versus Pritchard’s regimen^ 1 [28] 126 F (NA) 0.25 (0.01, 6.05)
Comparison 3: magnesium sulphate IV maintenance versus IM maintenance: treatment of pre-eclampsia/eclampsia
3.1 Death
3.1.1 4 g IV LD; 0.75 g/hour IV MD versus Pritchard’s regimen^ 1 [29] 137 F (NA) 0.35 (0.04, 3.27)
3.2 Discontinuation or modification of treatment 2 [30,31] 317 F (0) 1.46 (0.83, 2.58)
3.2.1 6 g IV LD; 2 g/hour MD versus Pritchard’s regimen^ 1 [30] 17 F (NA) 3.33 (0.15, 71.90)
3.2.2 ‘Springfusor pump’ IV versus ‘Standard’ IM regimen 1 [31] 300 F (NA) 1.41 (0.79, 2.52)
3.3 Clinical signs of toxicity 2 [29,30] 154 R (38) 0.82 (0.05, 12.56)
3.3.1 4 g IV LD; 0.75 g/hour IV MD versus Pritchard’s regimen^ 1 [29] 137 F (NA) 0.21 (0.01, 4.27)
3.3.2 6 g IV LD; 2 g/hour MD versus Pritchard’s regimen^ 1 [30] 17 F (NA) 3.33 (0.15, 71.90)
3.4 Pain level ‘acceptable’
3.4.1 ‘Springfusor pump’ IV versus ‘Standard’ IM regimen 1 [31] 300 F (NA) 4.93 (3.59, 6.78)
3.5 Caesarean section 2 [29,30] 154 F (0) 1.03 (0.78, 1.35)
3.5.1 4 g IV LD; 0.75 g/hour IV MD versus Pritchard’s regimen^ 1 [29] 137 F (NA) 0.99 (0.75, 1.32)
3.5.2 6 g IV LD; 2 g/hour MD versus Pritchard’s regimen^ 1 [30] 17 F (NA) 1.50 (0.47, 4.76)
3.6 Postpartum haemorrhage
3.6.1 4 g IV LD; 0.75 g/hour IV MD versus Pritchard’s regimen^ 1 [29] 137 F (NA) 0.35 (0.04, 3.27)
Comparison 4: short versus standard (24 hours) postpartum magnesium maintenance therapy: treatment of pre-eclampsia
4.1 Toxicity 2 [32,33] 256 F (NA) 0.25 (0.06, 1.08)
4.1.1 Short (12 h) versus standard (24 h) 1 [32] 196 F (NA) No toxicity
4.1.2 Short (based on clinical criteria) versus standard (24 h) 1 [33] 60 F (NA) 0.25 (0.06, 1.08)
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Table 2 Adverse effect estimates from randomised controlled trials (Comparisons 2–4) (Continued)
4.2 Side effects
4.2.1 Short (based on clinical criteria) versus standard (24 h) 1 [33] 60 F (NA) 0.17 (0.02, 1.30)
4.3 ‘Intolerance’
4.3.1 Short (based on clinical criteria) versus standard (24 h) 1 [33] 196 F (NA) No intolerance
^Pritchard’s regimen: 4 g IV and 10 g IM LD; 5 g IM MD/4 hours.
*Dhaka regimen: 4 g IV and 6 g IM LD; 2.5 g IM/4 hours.
~Bhalla regimen: 4 g IV and 8 g IM LD; 4 g IM/4 hours.
I2statistics is a test of heterogeneity; where I2 was > 30% summary estimates were calculated using random-effects meta-analysis; the bold effect estimates
indicate statistical significance.
Abbreviations: CI confidence interval, F fixed-effect, g gram, h hour, IM intramuscular, IV intravenous, LD loading dose, MD maintenance dose, NA not applicable,
R random-effects, RR risk ratio.
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maintenance therapy: prevention of eclampsia
This comparison included two trials with 260 women
which assessed magnesium sulphate for the prevention
of eclampsia (see Table 2 and Additional file 5 for effect
estimates and forest plots for Comparison 4). The trials
compared individualised (short) versus standard (24 hour)
postpartum maintenance therapy [32,33]. One trial com-
pared 2 g/hour IV maintenance for 12 hours versus for
24 hours [32], whilst the other trial compared individ-
ualised maintenance (based on clinical criteria) with
24 hours maintenance; the regimens were unclear [33].
Life-threatening adverse effects of treatment
There were no data on the primary outcomes.
Adverse effects associated with treatment
There were insufficient data for reliable conclusions
about the differential effects on ‘toxicity’ in two trials
(RR 0.23; 95% CI 0.06 to 1.08; 256 women; Analysis 4.1),
or ‘side effects’ in one trial (RR 0.17; 95% CI 0.02 to
1.30; 60 women; Analysis 4.2). There were no cases of
‘intolerance’ among women in either group in the one
trial of 196 women reporting this outcome (Analysis 4.3).
Comparison 5: lower dose versus higher dose IV
maintenance: prevention of preterm birth
This comparison included two trials with 260 women
(see Table 3 and Additional file 5 for effect estimates and
forest plots for Comparison 5). Both trials assessed mag-
nesium sulphate for the prevention of preterm labour,
comparing a 4 g loading dose and 2 g/hour maintenance,
with either a 6 g loading dose and ≥ 2 g/hour maintenance
[34] or a 4 g loading dose and 5 g/hour maintenance [35].
Life-threatening adverse effects of treatment
The two trials did not report on the review’s primary
outcomes.
Interventions to limit adverse effects
There was no cessation due to adverse effects in either
trial (Analysis 5.1).Adverse effects associated with treatment
No significant difference was shown for the outcome ‘no
side effects’ when data for the two trials were pooled
(RR 1.55; 95% CI 0.94 to 2.84; 248 women; Analysis 5.2),
however there was a substantial degree of statistical het-
erogeneity for this outcome (I2 = 63%), and the subgroup
interaction test indicated a potential differential effect
based on the comparison regimen (Chi2 = 2.73, P = 0.10,
I2 = 63.4%). In one trial, women receiving the lower dose
IV maintenance regimen (2 g/hour) were significantly
more likely to experience ‘no side effects’ than women
receiving the higher dose maintenance regimen (5 g/hour)
(RR 1.96; 95% CI 1.35 to 2.84; 148 women; Analysis 5.2.2).
No significant difference was shown between the low and
high dose IV maintenance groups for flushing (RR 0.61;
0.33 to 1.12; 2 trials, 248 women; Analysis 5.3), however
moderate statistical heterogeneity was also observed for
this outcome, which may be in part explained by the
differing high dose comparison regimens.
There were insufficient data for reliable conclusions
about the differential effects on the risk of nausea and
vomiting (RR 0.79; 95% CI 0.45 to 1.37; 1 trial, 100 women;
Analysis 5.4) and headache (RR 0.56; 95% CI 0.30 to
1.05; 2 trials. 248 women; Analysis 5.5).Other outcomes
No significant differences were shown between groups
for the outcomes caesarean section (RR 1.11; 95% CI 0.73
to 1.70; 2 trials, 248 women; Analysis 5.6) and pulmonary
oedema (RR 0.21; 95% CI 0.03 to 1.76; 2 trials, 260 women;
Analysis 5.7).Comparison 6: ready to use solution versus reference
drug requiring dilution: prevention of preterm birth
This comparison included one trial of 46 women (see
Table 3). The trial compared a pre-mixed ‘ready-to-use’
solution of magnesium sulphate, with a reference drug,
a commercially available infusion solution concentrate
requiring dilution [36]. All women were given a 4 g IV
loading dose followed by 1-2 g/hour IV maintenance.
Table 3 Adverse effect estimates from randomised controlled trials (Comparisons 5–6)
Outcome or subgroup Studies Participants Method (I2(%))* RR (95% CI)
Comparison 5: lower dose versus higher dose magnesium sulphate IV maintenance: tocolysis
5.1 Cessation due to adverse effects 2 [34,35] 248 F (NA) No cessation
5.2 No side effects 2 [34,35] 248 R (63) 1.55 (0.94, 2.58)
5.2.1 4 g LD; 2 g/h MD versus 6 g LD; ≥ 2 g/h MD 1 [34] 100 F (NA) 1.17 (0.71, 1.91)
5.2.2 4 g LD; 2 g/h MD versus 4 g LD; 5 g/h MD 1 [35] 148 R (NA) 1.96 (1.35, 2.84)
5.3 Flushing 2 [34,35] 248 R (60) 0.61 (0.33, 1.12)
5.3.1 4 g LD; 2 g/h MD versus 6 g LD; ≥ 2 g/h MD 1 [34] 100 F (NA) 0.87 (0.46, 1.63)
5.3.2 4 g LD; 2 g/h MD versus 4 g LD; 5 g/h MD 1 [35] 148 F (NA) 0.46 (0.29, 0.73)
5.4 Nausea and vomiting
5.4.1 4 g LD; 2 g/h MD versus 6 g LD; ≥ 2 g/h MD 1 [34] 100 F (NA) 0.79 (0.45, 1.37)
5.5 Headache 2 [34,35] 248 F (0) 0.56 (0.30, 1.05)
5.5.1 4 g LD; 2 g/h MD versus 6 g LD; ≥ 2 g/h MD 1 [34] 100 F (NA) 0.80 (0.23, 2.81)
5.5.2 4 g LD; 2 g/h MD versus 4 g LD; 5 g/h MD 1 [35] 148 F (NA) 0.50 (0.24, 1.03)
5.6 Caesarean 2 [34,35] 248 F (0) 1.11 (0.73, 1.70)
5.6.1 4 g LD; 2 g/h MD versus 6 g LD; ≥ 2 g/h MD 1 [34] 100 F (NA) 1.31 (0.78, 2.21)
5.6.2 4 g LD; 2 g/h MD versus 4 g LD; 5 g/h MD 1 [35] 148 F (NA) 0.88 (0.43, 1.80)
5.7 Pulmonary oedema 2 [34,35] 260 F (NA) 0.21 (0.03, 1.76)
5.7.1 4 g LD; 2 g/h MD versus 6 g LD; ≥ 2 g/h MD 1 [34] 100 F (NA) No oedema
5.7.2 4 g LD; 2 g/h MD versus 4 g LD; 5 g/h MD 1 [35] 160 F (NA) 0.21 (0.03, 1.76)
Comparison 6: ‘ready-to-use’ magnesium sulphate solution versus a reference drug requiring dilution: tocolysis
6.1 Death 1 [36] 46 F (NA) No deaths
6.2 ‘Serious’ adverse events 1 [36] 46 F (NA) No serious events
6.3 Withdrawn from the study due to adverse effects 1 [36] 46 F (NA) 0.67 (0.12, 3.62)
6.4 Adverse events of ‘severe intensity’ 1 [36] 46 F (NA) 0.67 (0.22, 2.05)
6.5 1 or 2 injection site changes 1 [36] 46 F (NA) 1.00 (0.28, 3.52)
6.6 Poor general tolerability (physician assessed) 1 [36] 43 F (NA) 3.14 (0.13, 72.96)
6.7 Respiratory depression 1 [36] 46 F (NA) 0.20 (0.10, 3.95)
6.8 Warmth (mild, severe, very severe) 1 [36] 41 F (NA) 0.84 (0.42, 1.69)
6.9 Nausea and/or vomiting (mild, severe, very severe) 1 [36] 41 F (NA) 0.536 (0.11, 2.56)
6.10 Tiredness (mild, severe, very severe) 1 [36] 41 F (NA) 1.18 (0.57, 2.45)
6.11 Headache (mild, severe, very severe) 1 [36] 41 F (NA) 0.92 (0.41, 2.06)
6.12 Dry mouth (mild, severe, very severe) 1 [36] 41 F (NA) 0.82 (0.38, 1.77)
6.13 Dizziness (mild, severe, very severe) 1 [36] 41 F (NA) 1.05 (0.30, 3.64)
6.14 Sweating (mild, severe, very severe) 1 [36] 41 F (NA) 1.31 (0.41, 4.20)
6.15 Skin redness (mild, severe, very severe) 1 [36] 41 F (NA) 1.75 (0.48, 6.38)
6.16 Burning at injection site (mild, severe, very severe) 1 [36] 41 F (NA) 0.42 (0.16, 1.12)
6.17 Palpitations (mild, severe, very severe) 1 [36] 41 F (NA) 1.58 (0.29, 8.46)
6.18 Constipation (mild, severe, very severe) 1 [36] 41 F (NA) 4.20 (0.51, 34.44)
6.19 Dyspnoea (mild, severe, very severe) 1 [36] 41 F (NA) No dyspnoea
6.20 Heart pain (mild, severe, very severe) 1 [36] 41 F (NA) 0.35 (0.20, 8.10)
6.21 Agitation (mild, severe, very severe) 1 [36] 41 F (NA) 4.20 (0.51, 34.44)
I2statistics is a test of heterogeneity; where I2 was > 30% summary estimates were calculated using random-effects meta-analysis; the bold effect estimates
indicate statistical significance.
Abbreviations: CI confidence interval, F fixed-effect, g gram, h hour, IV intravenous, LD loading dose, MD maintenance dose, NA not applicable, R random-effects,
RR risk ratio.
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Figure 5 Risk of bias for non-randomised controlled trials. Risk of
bias summary showing review authors’ judgements about each risk
of bias item for included non-randomised controlled trials. Each risk
of bias item is judged as at a low risk of bias, unclear risk of bias or
high risk of bias.
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http://www.biomedcentral.com/1471-2393/13/195Life-threatening adverse effects of treatment
There were no maternal deaths, or ‘serious’ adverse
events in either group (Analysis 6.1 and 6.2). There were
no data on other primary outcomes.
Interventions to limit adverse effects
There were insufficient data for reliable conclusions
about the differential effects on ‘withdrawing from the
study due to adverse effects’ (Analysis 6.3) and one or
two injection site changes (Analysis 6.5).
Adverse effects associated with treatment
There were insufficient data for reliable conclusions
about the differential effects on any of the adverse effects
reported in the trial (adverse events of severe intensity,
poor general tolerability, respiratory depression, warmth,
nausea and/or vomiting, tiredness, headache, dry mouth,
dizziness, sweating, skin redness, burning at injection
site, palpitations, constipation, dyspnoea, heart pain,
agitation) (Analyses 6.4 and 6.6 to 6.21).
Other outcomes
The trial did not assess other outcomes of interest.
Evidence from non-randomised comparative studies with
concurrent controls
Fourteen non-randomised comparative studies with con-
current controls were included (3,615 women) [37-51]:
four non-randomised clinical trials (969 women) [46-49],
four prospective before and after studies (78 women)
[40-43], five retrospective cohort studies (2,502 women)
[37-39,45,51] and one retrospective case-control study
(66 women) [44]. Additionally, one historical control study
was included (76 women) [50]. The detailed characteris-
tics of the studies are presented in Additional file 4, with
the risk of bias assessment presented in Figures 5 and 6.
For the four non-randomised trials, sequence generation,
allocation concealment and blinding were not considered
adequate (Figure 5). In regards to other comparative
studies, for the majority of studies, selection, according
to principles of the Newcastle-Ottawa Scale [14], was
considered adequate (7/11), whilst comparability was
largely unclear or not considered adequate, and outcome
or exposure assessment was largely unclear (Figure 6).
Results from these studies largely supported those
from the randomised trials (see Tables 4 and 5), with no
major maternal complications (including death and car-
diac arrest) in the studies that reported these outcomes.
Figure 6 Risk of bias for non-randomised comparative studies
with concurrent controls~. Risk of bias summary showing review
authors’ judgements about each risk of bias item for included
non-randomised comparative studies with concurrent controls.
Each risk of bias item is judged as at a low risk of bias, unclear risk
of bias or high risk of bias. ~This includes one historical control study.
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of treatment due to adverse effects [45], the percentage
of women stopping treatment was similar to the per-
centages reported in the randomised trials (Table 5).
Effect estimates from non-randomised studies for the
risk of caesarean section for women receiving magnesium
sulphate versus no magnesium sulphate, were notably
higher than the pooled effect estimate from the randomisedtrials (Table 4). In two retrospective cohort studies, women
receiving magnesium sulphate were significantly more
likely to experience failed labour induction [39], and
undergo caesarean section due to failure to progress
[37] (Table 4).
No significant increase in neuromuscular weakness
among women receiving nifedipine as their antihyper-
tensive during magnesium sulphate therapy, compared
with women receiving an alternative or no antihyperten-
sive agent, was shown in one retrospective cohort [45]
(Table 4). Significantly increased risks of thirst, respira-
tory problems and minor bleeding, were however ob-
served among women receiving nifedipine, compared
with no antihypertensive agent; a significantly increased
risk of neuromuscular blockade was observed among
women receiving an alternative antihypertensive, com-
pared with nifedipine [45] (Table 4). Whilst two pro-
spective before and after studies showed a significant
increase in bleeding time for women receiving magne-
sium sulphate [40,41] (Table 4), this was not supported
by an increased risk of postpartum haemorrhage in the
randomised trials (Table 1). Similarly, whilst in one
retrospective case control study, pregnant women with
pulmonary oedema were significantly more likely to
have received magnesium sulphate as compared with
women without pulmonary oedema [44] (Table 4), the
randomised trials did not support an increased risk of
pulmonary oedema overall (Table 1).
In one retrospective study, women receiving magne-
sium sulphate for greater than 48 hours compared with
for less than 48 hours had a significantly increased risk
of experiencing more than one adverse effect [51] (Table 5).
No significant differences were seen, however, in the
risk of discontinuing therapy due to adverse effects, or
for any other adverse effects [51] (Table 5). In one non-
randomised trial, women allocated to a loading dose
only, compared with women receiving Pritchard’s regi-
men (a loading dose of 4 g IV and 10 g IM, and 5 g IM
every four hours as maintenance), were significantly
less likely to experience nausea and vomiting, dizziness,
irritation at the injection site, and undergo a caesarean
section [49] (Table 5). Similar to the randomised trials,
a significantly increased risk of pain was experienced
among women receiving IM versus IV maintenance therapy
[46] (Table 5). Supporting the findings from one random-
ised trial, no significant differences in adverse effects or
medication errors were shown in the historical control
study that assessed two different magnesium sulphate
solutions using an identical dosage regimen [50] (Table 5).
Evidence from case series
Thirty-two studies [52-83] (3,276 women), 20 prospective
and 12 retrospective in nature, reporting maternal adverse
effects were included; the characteristics of the studies
Table 4 Adverse effect estimates from comparative studies with concurrent controls
Study Participants and comparison Adverse effect Estimates P-value or effect estimate
(95% CI)
Magnesium sulphate versus no magnesium sulphate
Ales 1987 [37] 178 women. MgSO4 for H (n = 64) v no MgSO4 (n = 114) Caesarean 39.1 v 29.0% AOR 2.81 (1.99, 3.62)^
Caesarean (failure to progress) 72.0% v 42.4% OR 3.49 (1.15, 10.62)
Seyb 1999 [38] 1561 women. MgSO4 for PE (n = 54) v no MgSO4 (n = 1507) Caesarean 22.2% v 10.2% OR 2.53 (1.30, 4.91)
Caesarean AOR 2.18 (1.04, 4.55)*
Park 2006 [39] 231 women. MgSO4 for PE (n = 29) v no MgSO4 (n = 202) Failed induction of labour AOR 17.78 (1.62, 195.14)~
Assaley 1998 [40] 18 women. MgSO4 for PE (n = 15) v no MgSO4 (n = 3) Significant ↑ in bleeding time with MgSO4
(v no significant change with no MgSO4)
P < 0.0043
Kynczl-Leisure 1996 [41] 12 women. MgSO4 for PE (n = 9) v no MgSO4 (n = 3) Significant ↑ in bleeding time with MgSO4
(v no significant change with no MgSO4)
P < 0.01
Ramanathan 1988 [42] 16 women. MgSO4 for PE (n = 10) v no MgSO4 (n = 6) Significant ↓ in pulmonary function (FVC (L),
FEV1(L), MVV (L)) with MgSO4 (v no significant
change with no MgSO4)
P < 0.005; P < 0.01; P < 0.02
Ramanathan 1988 [43] 32 women. 1. Labour augmentation and MgSO4 for PE
(n = 16) v 2. MgSO4 postpartum for PE (n = 6) v 3. Labour
induction and no MgSO4 (n = 10)
Depression of neuromuscular transmission for
Groups 1 and 2 (before MgSO4 to during MgSO4)
v no changed for Group 3 (before and during
induction, and postpartum)
Poggi 2003 [44] 66 women. Pulmonary oedema (n = 15) v no pulmonary
oedema (n = 51)
Case (pulmonary oedema) v control MgSO4
exposure (for PE or PTL)
93.3% v 62.7% P = 0.049
All women received magnesium sulphate: comparison based on antihypertensive agent received
Magee 2005 [45] 377 women who all received MgSO4 for PE. 1. Nifedipine
(n = 162) v 2. Other antihypertensive (n = 32) v 3. No
antihypertensive (n = 183)
Calcium gluconate given 0.5% v 3.1% v 0.0% P = 0.30 (1v2); P = 0.47 (1v3)
Infusion stopped due to adverse effects 1.2% v 3.1% v 4.9% P = 0.42 (1v2); P = 0.05 (1v3)
Infusion reduced due to adverse effects 8.0% v 3.1% v 7.7% P = 0.47 (1v2); P = 0.90 (1v3)
Neuromuscular weakness 53.1% v 53.1% v 44.8% P = 0.99 (1v2); P = 0.13 (1v3)
Absent deep tendon reflexes 5.6% v 6.3% v 3.8% P = 0.12 (1v2); P = 0.22 (1v3)
Weakness 15.4% v 28.1% v 10.9% P = 0.99 (1v2); P = 0.26 (1v3)
Respiratory depression 9.9% v 9.4% v 6.6% P = 0.99 (1v2); P = 0.45 (1v3)
Neuromuscular blockade 0.0% v 6.25% v 0.0% P = 0.03 (1v2); P = NA (1v3)
Maternal hypotension 41.4% v 31.3% v 53.0% P = 0.33 (1v2); P= 0.04 (1v3)
Nausea/vomiting 49.4% v 43.8% v 47.0% P = 0.70 (1v2); P = 0.66 (1v3)
Drowsiness/confusion 45.7% v 37.5% v 38.3% P = 0.44 (1v2); P = 0.16 (1v3)
Dizziness 28.4% v 25.0% v 20.8% P = 0.83 (1v2); P = 0.10 (1v3)



















Table 4 Adverse effect estimates from comparative studies with concurrent controls (Continued)
Thirst 20.4% v 21.9% v 7.1% P= 0.81 (1v2); P<0.001 (1v3)
Respiratory problems 14.8% v 6.3% v 7.7% P = 0.26 (1v2); P = 0.03 (1v3)
Dyspnoea 8.6% v 0.0% v 4.9% P = 0.13 (1v2); P = 0.17 (1v3)
Pulmonary oedema 2.5% v 0.0% v 1.1% P = 0.99 (1v2); P = 0.57 (1v3)
Oxygen required 4.9% v 3.1% v 2.2% P = 0.99 (1v2); P = 0.16 (1v3)
Maternal tachycardia 22.2% v 18.8% v 14.2% P = 0.82 (1v2); P = 0.05 (1v3)
Itchy/tingling 14.8% v 18.8% v 15.3% P = 0.60 (1v2); P = 0.90 (1v3)
Tremulous 6.8% v 9.4% v 2.7% P = 0.27 (1v3)
Minor bleeding 4.9% v 6.3% v 0.0% P= 0.67 (1v2); P=0.002 (1v3)
Chest pain 5.6% v 6.3% v 2.7% P = 0.99 (1v2); P = 0.19 (1v3)
The bold effect estimates indicate statistical significance. ^Logistic regression was used to adjust for age, race, parity, physician status, obesity, gestational age, and mean arterial pressure during labour; * “Controlling
for the significant confounding variables”; ~ “logistic regression analyses…adjusting for the potential confounding variables”.
Abbreviations: AOR adjusted odds ratio, CI confidence interval, FEV1 forced expiratory volume at 1 second, FVC forced vital capacity, H hypertension, MgSO4 magnesium sulphate, MVV maximum voluntary ventilation,



















Table 5 Adverse effect estimates from comparative studies with concurrent controls
Study Participants and comparison Adverse effect Estimates Effect estimate (95% CI)
Magnesium sulphate versus no magnesium sulphate
Chowdhury 2000 [46] 630 women (E). Low dose IV (4 g IV LD over 2–3 mins;
5 g/8 h IV MD) (n = 150) v Pritchard’s IM regimen
(4 g IV and 10 g IM LD; 5 g/4 h IM MD) (n = 480)
Major adverse effects; respiratory depression 0.0% v 0.0% NA
Absent knee jerks and oliguria; stopped dosing due to adverse e cts 0.0% v 3.2% RR 0.10 (0.01, 1.71)
Pain at injection site 0.0% v 55.0% RR 0.01 (0.00, 0.10)
Mahajan 2007 [47] 95 women (E). 1. (2 g IV and 4 g IM LD; 4 g IM/4 h)
(n = 37) v 2. (2 g IV and 8 g IM LD; 4 g IM/4 h) (n = 58)
Respiratory depression 0.0% v 0.0% NA
Absent knee jerks and MD omitted 56.8% v 31.0% RR 1.83 (1.14, 2.94)
Young 1977 [48] 144 women (PE or E). 1. (10 g IM LD; 2 g slow IV ‘push’
with repeated doses every 1–2 h) (n = 97) v 2.
(10 g IM LD; continuous IV 1 g/h) (n = 47)
Death 0.0% v 0.0% NA
Heat and flushing 92.8% v 0.0% RR 88.65 (5.62, 1397.80)
Respiratory effects (slowing respirations to complete apnoea) 79.4% v 0.0% RR 75.92 (4.81, 1198.55)
Shoaib 2009 [49] 100 women (severe PE). LD only (4 g IV and 10 g IM LD)
(n = 50) v Pritchard’s IM regimen (4 g IV and 10 g IM LD;
5 g/4 h IM) (n = 50)
Death; respiratory failure or distress; cardiac arrest 0.0% v 0.0% NA
Nausea and vomiting 10.0% v 34.0% RR 0.29 (0.12, 0.74)
Warmth and flushing 70.0% v 80.0% RR 0.88 (0.70, 1.10)
Dizziness 20.0% v 56.0% RR 0.36 (0.19, 0.65)
Irritation at the injection site 0.0% v 20.0% RR 0.05 (0.00, 0.79)
Caesarean 12.0% v 30.0% RR 0.40 (0.17, 0.95)
Palmer 2009 [50] 76 women (PE). New protocol (20% solution, separate
LD and MD bags) (n = 29) v Old protocol
(2-8% solution, same LD and MD bag) (n = 47)
Phlebitis; signs or symptoms of toxicity 0.0% v 0.0% NA
Calcium gluconate (for hypocalcaemia) 3.5% v 4.3% RR 0.81 (0.08, 8.54)
Errors (failure to reset pump after LD) 0.0% v 4.3% RR 0.32 (0.02, 6.44)
Errors (change in drug order) 3.5% v 2.1% RR 1.62 (0.11, 24.92)
Nassar 2006 [51] 155 women (PTL). 1. Treatment for > 48 hours
(n = 78) v 2. Treatment for < 48 hours (n = 77)
≥ 1 adverse effect 30.8% v 15.6% OR 2.41 (1.10, 5.26)
Discontinuation due to adverse effects 6.4% v 0.0% OR 11.60 (0.63, 213.47)
Chest tightness 19.2% v 11.8% OR 1.80 (0.74, 4.40)
Visual disturbances 6.4% v 1.3% OR 5.21 (0.59, 45.63)



















Table 5 Adverse effect estimates from comparative studies with concurrent controls (Continued)
Pulmonary oedema 6.4% v 2.6% OR 2.57 (0.48, 13.66)
Ileus 3.8% v 1.3% OR 3.04 (0.31, 29.89)
Osteopenia 2.6% v 0.0% OR 5.07 (0.24, 107.25)
Hypocalcaemia (< 8.5 mg/dl) 24.6% v 15.6% OR 1.77 (0.74, 4.21)
The bold effect estimates indicate statistical significance.
Abbreviations: CI confidence interval, E eclampsia, g grams, h hours, IM intramuscular, IV intravenous, LD loading dose, MgSO4 magnesium sulphate, MD maintenance dose, mins minutes, OR odds ratio,
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file 4. Adverse effects have been presented in Table 6 as
overall mean and median percentage estimates calcu-
lated from individual study results, with the range of
percentages reported in the studies also presented. For
the quality assessment of case series, we predominately
considered participant selection, along with the collection/
reporting of adverse effect information, as detailed in
Additional file 4.
Adverse effect estimates reported in case series were
largely similar to those reported in the randomised trials
in Comparison 1 (see Additional file 6). Mean/median
percentage estimates of serious outcomes, respiratory
arrest, the use of calcium gluconate and discontinuation
of therapy due to adverse effects, were slightly higher in
the case series. The estimates for the outcome ‘any
maternal adverse effects’ reported in case series were
however notably lower than those in the randomised
trials. The case series estimates for nausea and/or vomiting,
blurred vision and hypotension were higher than estimates
from the randomised trials.
Evidence from case reports
Seventy-five studies describing a total of 137 case reports
of maternal adverse effects were included [84-158] (see
Table 7; the more detailed characteristics of cases are
presented in Additional file 7).
Iatrogenic overdoses (16 reports) [84-100] and rapid
administration of magnesium sulphate (one report) [86]
were associated with a range of serious adverse events,
such as respiratory arrest, cardiac arrest, cardiopulmo-
nary arrest and death. Of note was a detailed account of
52 errors associated with magnesium sulphate administra-
tion; including seven cases resulting in death, or women
remaining in a persistent vegetative state [87]. Additional
errors, relating to the epidural or intrathecal adminis-
tration of magnesium sulphate were associated with
pain, inadequate pain relief, or temporary paralysis (four
reports) [101-104].
Women at an increased risk of adverse effects were
described (11 reports) (105-115), including women with
renal failure (three reports) [113-115], and women with
neuromuscular junction disorders, myopathies, and neu-
ropathologies (eight reports) [105-112]. For the neuro-
logical cases, magnesium sulphate administration, according
to recommended regimens, was associated with muscle
pain, weakness or temporary paralysis, and associated
respiratory problems. The interaction of magnesium
sulphate with agents used in general anaesthesia (10
reports) [116-125] and with antihypertensive agents in-
cluding nifedipine (six reports) [126-131] was associated
with varying adverse effects, most commonly muscular
weakness or paralysis, and altered respiratory function –
associated with prolonged neuromuscular blockade.A variety of unusual maternal adverse effects, not pre-
viously attributed to magnesium sulphate, were described
(11 reports) [132-142], including bilateral progressive
labial swelling [132], marked osteoporotic change [136],
and urinary tract stone formation [139]; in such cases
women had received prolonged magnesium sulphate
tocolysis therapy. Additional adverse effects, such as
hypotension and fatigue as reported in randomised trials,
were detailed (16 reports) [143-158]. Of note were five
reports where adverse effects such as delirium [156], dip-
lopia [153], tetany and paraesthesia [152-154] associated
with serum hypocalcaemia, were described.Evidence from patient safety organisations
Whilst the majority of patient safety organisations did
not provide free access to their adverse event or equiva-
lent databases, information regarding medication errors
and maternal adverse effects associated with antenatal
magnesium sulphate was available from the Institute for
Safe Medication Practices USA. The Institute provided
accessible information in their electronic medication safety
newsletters. Three cases of serious iatrogenic overdose were
reported in the 12 February 1997 issue [159]. Whilst the
women survived, one suffered a respiratory arrest, and
one, temporary paralysis of her extremities, ICU admis-
sion and the need for prolonged ventilation. Additional
cases were described in the 30 June 1999, 15 June 2005,
20 October 2005, and 3 June 2010 issues.
The February 2010 issue of the Patient Safety Newsletter
‘Sharing Lessons Leaned’ produced by the Office of Safety
and Quality in Health Care, Western Australia, reported
12 incidents involving magnesium sulphate overdose from
October 2001 to October 2009, identified through searches
of state-wide relevant databases [160]; the consequent ma-
ternal adverse effects were not however discussed.Women’s experiences – from personal blogs and
discussion forum threads
(See Additional file 8 for blog and discussion forum
thread sources).Before treatment
Women considered information regarding others’ expe-
riences with magnesium sulphate important, with a par-
ticular desire for knowledge regarding adverse effects
and their severity; a number of women expressed an ex-
plicit wish for “the truth, no matter how bad or scary.”
Women expressed expectations of treatment benefits,
relating to the different indications for use, and also
concern and a sense of fear regarding the possible adverse
effects of treatment; one woman exclaimed “What?!! NO!!!
ANYTHING BUT MAG!!!”
Table 6 Adverse effect estimates from comparative studies with concurrent controls
Adverse effect Mean (%) or effect Median (%) Range (%) Women Studies
Death 0.14 0.00 0 to 0.41 285 Adewole 2000* [53]; Ekele 2005* [54]; Pritchard 1984* [55]
Cardiac arrest 0.00 0.00 NA 21 Adewole 2000* [53]
Respiratory arrest 0.41 0.42 0 to 0.82 983 Adewole 2000* [53]; Pritchard 1984* [55]; Raman 1995* [56]
Discontinuation due to adverse effects 9.53 9.52 1.75 to
20.78
532 Adewole 2000* [53]; Elliot 1983^ [57]; Girard 2005* [58];
Harding 1997* [59]; Thapa 2008* [60]
Given calcium gluconate 0.70 0.70 NA 717 Raman 1995* [56]
‘Toxicity’ 3.17 2.04 0.0 to 8.60 182 Dasari 2010* [61]; Donovan 1980* [62];
Mojadidi 1969* [63]; Tukur 2010* [64]
Need to adjust/skip dose due to adverse effects 15.26 15.26 5.26 to
25.26
114 Ekele 2005* [54]; Getaneh 2010*^ [65]
Respiratory depression 1.67 0.72 0 to 4.76 1363 Adewole 2000* [53]; Ahmed 2004* [66]; Begum 2001* [67];
Digre 1990^ [68]; Ekele 2005* [54]; Hales 1995^ [69];
Harding 1997* [59]; Mojadidi 1969* [63]; Pritchard 1984* [55];
Raman 1995* [56]; Sass 2007* [70]
Absent or reduced deep tendon reflexes 4.75 2.55 0 to 18.05 1789 Aali 2007* [52]; Begum 2001* [67]; Digre 1990^ [68]; Donovan 1980* [62];
Ekele 2005* [54]; Hales 1995^ [69]; Omu 2008* [71]; Pritchard 1984* [55];
Raman 1995* [56]; Sass 2007* [70]
Any adverse effects 13.39 14.29 6.76 to
19.11
826 Adewole 2000* [53]; Elliot 1983^ [57]; Omu 2008* [71]
‘Minor side effects’ 1.75 1.75 NA 57 Girard 2005* [58]
Hypotension 30.56 30.56 NA 72 Hales 1995^ [69]
Flushing or warmth 52.88 52.88 4.55 to 100 27 Cotton 1984* [72]; Harding 1997* [59]
Nausea and/or vomiting 47.37 38.46 3.66 to 100 373 Cotton 1984* [72]; Digre 1990^ [68]; Elliot 1983^ [57]
Generalised weakness 23.08 23.08 NA 13 Digre 1990^ [68]
Drowsiness or confusion 2.58 2.90 0.28 to 4.55 515 Elliot 1983^ [57]; Harding 1997* [59]; Sass 2007* [70]
Headache 2.90 0.72 0.28 to 7.69 506 Digre 1990^ [68]; Elliot 1983^ [57]; Sass 2007* [70]
Blurred vision 46.30 46.30 0.28 to
92.31
368 Digre 1990^ [68]; Elliot 1983^ [57]
Diplopia 30.77 30.77 NA 13 Digre 1990^ [68]
Photophobia 30.77 30.77 NA 13 Digre 1990^ [68]
Visual signs 76.92 76.92 NA 13 Digre 1990^ [68]
Abnormal visual acuity 38.46 38.46 NA 13 Digre 1990^ [68]
Impaired concentration-confusion 23.08 23.08 NA 13 Digre 1990^ [68]
Cardiac arrhythmias 23.08 23.08 NA 13 Digre 1990^ [68]
Chest pain (and/or need for ECG) 3.90 3.90 0.85 to 6.94 427 Elliot 1983^ [57]; Hales 1995^ [69]



















Table 6 Adverse effect estimates from comparative studies with concurrent controls (Continued)
Delayed recovery from anaesthesia 0.14 0.14 NA 717 Raman 1995* [56]
Pulmonary oedema 1.25 1.25 1.13 to 1.36 649 Elliot 1983^ [57]; Yeast 1993*^ [73]
Caesarean 49.68 56.52 32.53 to
60.00
225 Aali 2007* [52]; Getaneh 2010*^ [65]; Pritchard 1984* [55]
Caesarean due to labour induction 48.91 51.85 33.33 to
61.54
109 Aali 2007* [52]; Getaneh 2010*^ [65]; Pritchard 1984* [55]
‘Transient nausea, vomiting, headache, flushing and palpitations’ NA NA NA 15 Jirapinyo 1990^ [74]
‘Magnesium toxicity suspected’ 2/49 deaths due to hypertensive disorders of pregnancy were
attributed to magnesium
Dasari 2010* [61]
Hospital errors in obstetric patients 146 hospital errors in obstetric patients (3rd most common
obstetric drug resulting in patient harm)
Kfuri 2008 ~ [75]
10 class 2 errors (need for additional treatment/
hospitalisation)
Little 2001 ~ [76]
‘Restrictive type of respiratory depression’ Sig ↓ in FVC (L) 18 Bilgin 1994* [77]
Decrease in respiratory function – ‘generalised respiratory
muscle weakness’
Sig ↓ MIP (cm H2O), MEP (cm H2O), FEV1 (L) 10 Herpolsheimer 1991* [78]
‘Reduced attention and rapid information processing ability’ Sig ↓ in SSS, PASAT, VAF, DSF scores 15 Ghia 2000^ [79]
Increase in bleeding time (‘clinical significance remains to be
determined’)
Sig ↑ 104 Fuentes 1995*^ [80], Guzin 2010* [81], Yazdani 2004^ [82]
NS ↑ 40 Moghadas 2007^ [83]
Values are presented as mean and median percentage estimates from case series, with the range of percentages reported.
*Women received MgSO4 for pre-eclampsia/eclampsia; ^women received MgSO4 as a tocolytic agent; ~unknown indication for use.
Abbreviations: AE adverse effect(s), DSF Digits Span Forward (Wechsler Adult Intelligence Scale), FVC forced vital capacity, FEV1 forced expiratory volume at 1 second, L litres, MIP maximal inspiratory pressure,



















Table 7 Adverse effect from case reports
Common theme and/or associated adverse effects Studies
Iatrogenic overdose (16 studies)
Death Anon 1990 [84]; Cohen 1992 [85]; Richards 1985 [86]
Death or persistent vegetative state Simpson 2004 (7 cases) [87]
Cardiopulmonary arrest McCubbin 1981 [88]; McDonnell 2009 [89]; Morisaki 2000 [90];
Rabinerson 1994 [91]; Swartjes 1992 [92]
Cardiac arrest Cohen 1992 [85]
Respiratory arrest Bohman 1990 [93]; Cao 1999 [94]; McKenna 2006 [95]; Wax 1995 [96]
“Life-threatening situation” Bruhwiler 1994 [97]
Coma Hayashi 2003 [98]
Ventilatory impairment; failure to rouse from general anaesthesia McDonnell 2010 [99]
Need for additional monitoring Buettner 2010 (2 cases) [100]
Variety (not death or remaining in a persistent vegetative state) Simpson 2004 (45 cases) [87]
Rapid administration (1 study)
Cardiac arrest Richards 1985 [86]
Unintended epidural or intrathecal administration (4 studies)
Bilateral periumbilical pain Dror 1987 [101]
Inadequate pain relief Goodman 2006 (2 cases) [102]
Paralysis of lower extremities Lejuste 1985 [103]; Lewis-Younger 2004 [104]
Increased risk of adverse effects – neuromuscular junction disorders, myopathies and neuropathologies (8 studies)
Weakness and/or temporary paralysis Bashuk 1990 [105]; Bruner 1990 [106]; Catanzarite 2008 [107]
Muscle pain and damage Hosono 2001 [108]
Acute respiratory insufficiently; ventilatory failure; respiratory depression Cohen 1976 [109]; Mueksch 2007 [110]; Robins 2007 [111]
“Magnesium toxicity” Moriarty 2008 [112]
Increased risk of adverse effects – renal failure (3 studies)
Decreased or absent deep tendon reflexes; prolonged QT interval Archer 2010 [113]
Muscle weakness Chan 2008 [114]
Progressive quadriparesis Nethravathi 2007 [115]
Drug interactions – agents used in general anaesthesia (10 studies)
Cardiac arrest Saitoh 1994 [116]
Respiratory arrest Baraka 1984 [117]
Failure to achieve adequate ventilation Nguyen 2001 [118]
Numb; difficultly moving upper extremities Fay 1996 [119]
Prolonged neuromuscular blockade Funai 2010 [120]; Hino 1997 [121]; Kwan 1996 [122]; Sinatra 1985 [123];
Yoshida 2006 (2 cases) [124]; Sloan 2001 [125]
Drug interactions – other agents (6 studies)
Neuromuscular blockade – muscle weakness or paralysis Ben-Ami 1994 [126]; Snyder 1989 [127]; Wu 2010 [128]
Extreme bradycardia Pittman 2000 [129]
Severe hypotension Scardo 1997 [130]; Waisman 1998 (2 cases) [131]
Unusual/unexpected adverse effects (11 studies)
Bilateral, progressive labial swelling (need for caesarean) Awwad 1994 [132]
Worsened clinical picture of appendicitis and cholecystitis Basaran 2007 [133]
Impaired lactogenesis Haldeman 1993 [134]
Severe paralytic ileus Hill 1985 [135]
Marked osteoporotic change (hips, knees, ankles) Hung 2005 [136]
Breast engorgement and galactorrhea Lurie 2002 [137]
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Table 7 Adverse effect from case reports (Continued)
Development of central pontine myelinolysis Riggs 2000 [138]
Urinary tract stone (magnesium ammonium phosphate) Sameshima 1997 [139]
Hyperkalaemia and hyponatremia (hyporeninemic hypoaldosteronism) Spital 1991 [140]
Left retinal detachment; partial right detachment Roberts 1998 [141]
Extensive urticarial rash Thorp 1989 (2 cases) [142]
Other adverse effects (16 studies)
Severe hypotension Bourgeois 1986 (2 cases) [143]; Rodis 1987 [144]
Hypothermia Cardosi 1998 [145]; Rodis 1987 [144]
Bradycardia (39-44/minute) Hennessy 1999 [146]
Asymptomatic atrial fibrillation (100-150/minute) Oettinger 1993 [147]
Absent deep tendon reflexes Pritchard 1979 [148]
Marked weakness; difficulty breathing Pritchard 1979 [148]
Sleepiness/fatigue; depressed/absent deep tendon reflexes Herschel 2001 [149]; Tang 2010 [150]
Chest pain; inverted T waves (ECG) (transient subendocardial ischemia) Sherer 1992 [151]
Pulmonary oedema Elliot 1979 [157]; Worrell 1992 [158]
Bilateral hand contractures; tetany (serum hypocalcaemia) Koontz 2004 (2 cases) [152]
Diplopia; malaise; paresthesia; hoarseness; tetany (serum hypocalcaemia) Mayan 1999 (2 cases) [153]
Hypotension; cyanosis; tetany (serum hypocalcaemia) Monif 1972 [154]
Chest tightness and pain; prolonged QT interval (serum hypocalcaemia) Nassar 2007 [155]
Delirium with myoclonus (serum hypocalcaemia) Ganzenvoort 2002 [156]
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Whilst variations in experiences existed, women described
a variety of adverse effects, the predominant being a
sensation of heat: “MY GOD, THE HEAT! I felt so hot
and it came from within.” Other commonly described
adverse effects were similar to those frequently reported
adverse effects in randomised trials – muscle weakness,
lethargy, blurred vision, nausea or vomiting, headaches,
confusion, arm discomfort, thirst, feeling sweaty and
dizzy. Less common adverse effects women attributed
to magnesium sulphate treatment included a failed in-
duction of labour and consequent need for a caesarean
section, the delayed onset of lactation, and the develop-
ment of pulmonary oedema. A number of women de-
scribed their request or the need for treatment cessation
due to adverse effects, with two women highlighting
their experience of being “accidentally overdosed.” Many
women portrayed their experience as terrifying, revealing
a sense of anguish.
After treatment
Women expressed relief following treatment cessation,
and great concerns regarding the possibility of treatment
in future pregnancies: “I pray I never have to do it again.”
A number of women felt information regarding the
possible adverse effects of treatment was miscommunicated
and misleading. Although many women recalled adverse ef-
fects of severe intensity, they were generally very thankful,and there was agreement among commenting women that
the potential perceived benefits of treatment outweighed
discomforts experienced, with magnesium sulphate being
described as “a necessary evil.”
Discussion
It is widely acknowledged that the use of antenatal mag-
nesium sulphate, for the prevention of eclampsia in
women with pre-eclampsia and the treatment of women
with eclampsia [1-4,9], to delay or prevent preterm birth
[5,6], and for neuroprotection of the fetus when given to
women at risk of preterm birth [7], may be associated
with adverse effects for the mother. The risk of individual
adverse effects, and how such adverse effects vary
according to different regimens, has however not been
clear. Determining this is of great importance given the
significant number of women who may be eligible for
treatment with magnesium sulphate during pregnancy –
with approximately 2-8% of pregnancies complicated by
pre-eclampsia [161], and an estimated 1-2% of births
being very preterm (before 32 weeks’ gestation) [162].
Summary of main results
We were able to include 21 randomised trials in this sys-
tematic review; 11 comparing magnesium sulphate with
placebo or no treatment, and 10 comparing different
magnesium sulphate regimens. Whilst ‘good’ data on
well recognised and easily detectable adverse effects may
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small numbers of participants, who may differ from indi-
viduals given the treatment in everyday practice, or the
short periods of time that the participants are studied
for, can reduce the possibility of unpredictable, rare or
delayed adverse effects being observed and reported
[12,163,164]. For such reasons, it was considered im-
portant to include other study designs. We included 15
non-randomised comparative studies with concurrent
controls, 32 case series, and 75 papers describing indi-
vidual case reports.
Evidence from the randomised trials assessing magne-
sium sulphate versus placebo or no treatment confirmed
the expected higher rates of ‘minor’ maternal adverse
effects among women receiving treatment, without an
increase in major complications (death, cardiac arrest,
respiratory arrest). The four randomised trials reporting
on ‘any adverse effects’ of treatment, showed an absolute
risk of 38% (2,521/6,642) for women exposed to antenatal
magnesium sulphate compared with 8.5% (567/6,680) for
women unexposed. Five randomised trials reported on the
need for cessation of treatment due to maternal adverse
effects, with significantly more women receiving magne-
sium sulphate having their therapy stopped compared
with women not receiving magnesium sulphate (6.6%
versus 2.4%). The most frequently reported adverse
effects included warmth or flushing, sweating, and arm
discomfort or problems at the IV site.
When considering indication for use and regimens
for administration, very few differences were observed
between the pre-specified subgroups. Considering indi-
cation for use, no significant subgroup interactions were
identified, expect for when considering arm discomfort,
which suggested a possible increase for women receiving
treatment for fetal neuroprotection (compared with women
receiving treatment for pre-eclampsia). When considering
regimen for administration for the trials comparing magne-
sium sulphate with placebo or no treatment, the subgroup
interaction tests did not indicate differential effects by
treatment subgroups. For the majority of outcomes, the
subgroups contained very few trials (many contained
only one), making comparisons between subgroups difficult.
The 10 randomised trials comparing different magne-
sium sulphate regimens were mostly too small to pro-
vide reliable evidence about the comparative effects of
different regimens on maternal adverse effects. Whilst
this review did not formally assess efficacy, none of the
trials demonstrated significantly decreased effectiveness
with the lower dose regimens. One trial reporting on the
cessation of treatment due to adverse effects showed sig-
nificantly more women receiving higher dose IM main-
tenance having their therapy ceased as compared with
women receiving lower dose IM maintenance (25.9% versus
1.4%). This was supported by one small non-randomisedtrial, reporting significantly higher rates of adverse effects
for women receiving Pritchard’s IM regimen versus a load-
ing dose only. One randomised trial showed significantly
more women receiving magnesium sulphate via an IV
pump reporting ‘acceptable’ pain as compared with women
receiving magnesium sulphate via the IM route (100%
versus 20%). This was supported by a non-randomised
trial that showed a significantly higher risk of pain among
women receiving magnesium sulphate via the IM route
versus via an IV infusion.
The data from the 32 case series largely supported that
from the randomised trials. Whilst serious outcome esti-
mates were broadly similar, differences between procedures
for collecting information on adverse events between
studies may help to explain the variations observed be-
tween estimates. Higher estimates for ‘any adverse ef-
fects’ in randomised trials may have been influenced by
the use of more rigorous methods for data collection,
such as the use of trial-specific check-lists [19]. The not-
ably higher estimates in case series for blurred vision
and nausea and/or vomiting similarly may have been
influenced by the use of specific questioning and inter-
viewing in regards to adverse effects [68], and incomplete
reporting, such as the use of generic statements [72].
As the establishment of a causal relationship between
a treatment and a subsequent adverse effect through in-
dividual cases is difficult, data presented in case reports
should be interpreted with a degree of caution. That
said, the significant harm that may result from accidental
overdose of magnesium sulphate is unquestionable. The
16 reports, including Simpson’s account of 52 errors associ-
ated with administration [87], highlight the potentially life-
threatening consequences of magnesium sulphate overdose.
Factors contributing to iatrogenic overdoses were identi-
fied [87]. These included: the inaccurate or inadequate
mixing of an IV magnesium sulphate solution, leading
to a higher concentration of solution than intended or
an undesirable concentration gradient between the infu-
sion bag and tubing; the use of infusion bags containing
a high total dose of magnesium sulphate, and the conse-
quent danger associated with infusion rate programming
error; the use of the same infusion bag for administration
of the loading and maintenance infusions, and the failure
to reduce the infusion rate following the loading dose; the
removal of an IV line from an IV pump temporarily, and
the accidental free-flow of solution; the handover of
clinical responsibilities in busy units, and the transfer of
women between units. Fortunately in most reported
cases, the error was recognised before permanent ad-
verse outcomes occurred. Monitoring of maternal status
(before, during and after administration of magnesium
sulphate), to allow signs and symptoms of toxicity to be
recognised, and for potential consequences of errors to
be mitigated in a timely manner, is imperative. Common
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sessment and documentation of vital signs (pulse, blood
pressure, respiratory rate), level of consciousness, patel-
lar reflexes and urinary output; and the provision of 1:1
nursing care during loading administration (and 1:2-3
care during maintenance or where 1:1 care is not pos-
sible) [87].
Case reports also highlighted the potential for an in-
creased risk of adverse effect occurrence among particu-
lar groups of women – those with renal insufficiency or
failure, and those with neuromuscular disorders such as
myasthenia gravis, Friedreich’s ataxia, myotonic dystrophy,
and other rare myopathies, such as mitochondrial myop-
athy. The potential for prolonged/enhanced neuromuscular
blockade when magnesium sulphate is used in conjunction
with general anaesthetic agents and antihypertensive agents
including nifedipine was also shown. Whilst this potential
interaction between magnesium sulphate and nifedipine
was highlighted, reassuringly no increased neuromuscular
blockade was shown in the retrospective cohort study that
compared the use of nifedipine versus other/no antihyper-
tensive during magnesium sulphate treatment (Table 4).
Though an excess of respiratory problems and minor
bleeding was shown among women receiving nifedipine,
compared with no antihypertensive, the condition of
women receiving nifedipine was considered compara-
tively more severe (more severe hypertension, more fre-
quent pre-eclampsia symptoms), which was suggested
to account for this difference [45].
Adverse effects not previously reported in randomised
trials that were discussed in case reports included marked
bilateral labial swelling, severe paralytic ileus, marked
osteoporotic change, and urinary tract stone formation
[132,135,136,139]. In each case, magnesium sulphate had
been used as a tocolytic agent for a prolonged period
(nine, three, 101 and 21 days respectively). The relevant
Cochrane reviews have shown magnesium sulphate to be
ineffective at delaying or preventing preterm birth [5,6].
Acknowledging this and the maternal adverse effects
of magnesium sulphate, from minor to unpleasant to
potentially fatal, its use as a tocolytic appears inappro-
priate, as has been strongly stated by Grimes and Nanda
[165]. Furthermore, the Food and Drug Administration
in the United States recently advised health care profes-
sionals against the use of magnesium sulphate as a
tocolytic for more than five to seven days due to associ-
ated harm to developing fetal bones (the use of the drug
for tocolysis is ‘off-label’ (not approved by the Food and
Drug Administration)) [166]. In view of the extremely
widespread use of antenatal magnesium sulphate in ob-
stetric practice, the potential neonatal and infant adverse
effects of antenatally administered magnesium sulphate
additionally require comprehensive evaluation, such as
by systematic review.Overall completeness, applicability and quality of
the evidence
This review was based on a comprehensive search strategy,
and whilst no language restrictions were applied, inclusion
was restricted to those studies written in English or for
which a translation was readily available, and to those
studies published in the databases that were searched,
which may have limited available studies. Additionally,
there were a number of articles that were excluded as
we were unable to obtain the abstract and/or full-text.
The included studies were however conducted in both
high-income and low-income countries, and are there-
fore may considered widely applicable to the treatment
of pregnant women.
The main limitations include the small number of
studies with relatively small sample sizes comparing dif-
ferent antenatal magnesium sulphate regimens, and the
missing data for several important outcomes in almost
all trials. Additionally, a great number of trials could not
be included in this review, as they did not provide any
information regarding maternal adverse effects of treat-
ment. This supports previous reports, that many trials
do not report harms, or do so in a fragmented or sub-
optimal way [167].
The studies included in the review were of mixed
quality and we emphasise the need to consider the risk
of bias as outlined in Figures 2, 3, 4, 5 and 6, and the
more detailed quality assessment in Additional file 4,
which includes consideration of the different procedures
used to collect information on adverse effects and reporting,
when interpreting results.
Potential biases in the review process
We recognise the potential for bias associated with the
second reviewer reviewing a random sample of the search
records (10% of the total), and independently extracting
data from a random sample of included studies (10%
of the total, and all 21 randomised controlled trials).
We attempted to minimise bias however in a number
of ways, for example by using a comprehensive search
strategy. Although this was extensive, it is possible that
some studies conducted in low- and middle-income
countries may not have been identified, if they were
not published, or published in journals not indexed in
the bibliographic databases searched.
Agreements and disagreements with other reviews
We are not aware of any other reviews specifically
assessing maternal adverse effects of antenatal magne-
sium sulphate, and comparing the adverse effects of dif-
ferent regimens for the various indications for use. The
findings of this review are broadly consistent with results
from relevant Cochrane reviews, comparing magnesium
sulphate with alternative drugs for women with eclampsia
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eclampsia [4], assessing magnesium sulphate for preventing
preterm birth in and after threatened preterm labour [5,6],
and evaluating magnesium sulphate for neuroprotection
of the fetus for women at risk of preterm birth [7].
These Cochrane reviews similarly concluded no in-
creased risk of major maternal complications (death,
cardiac arrest, respiratory arrest) for women receiving
magnesium sulphate according to those regimens used
in the trials [4,5,7], increased risks of many compara-
tively minor adverse effects [4,6,7], and an increased risk
of women ceasing treatment due to adverse effects [7].
One Cochrane review that assessed magnesium sulphate
for women with pre-eclampsia had previously shown a
small increased risk of caesarean section for women re-
ceiving magnesium sulphate, compared with placebo/no
treatment [4], as was suggested in this review.
The findings of this review largely support the meth-
odological conclusions from the systematic review by
Golder et al. [10] – that there are often limited differences
in the risk estimates of adverse effects derived from
randomised trials and observational studies. Further, they
highlight the importance of including a broad range of
study designs to ensure that the most complete picture of




By considering adverse effects alone, this review was not
designed to guide the choice of magnesium sulphate
regimen for the different antenatal indications for
use. Healthcare providers must therefore weigh the
potential risks of magnesium sulphate for the mother
against the benefits, for each known beneficial indica-
tion separately.
Vigilance in the use of magnesium sulphate is required
to promote and ensure safety for women. Certainly, errors
associated with the administration of magnesium sulphate
represent a significant and perhaps unappreciated risk
of harm. An important step in improving the safety for
women is knowledge and recognition of the risk of error;
this review, along with articles such as that published by
Simpson [87], may help in increasing awareness. Indi-
vidual hospitals should consider common precursors, or
contributing factors, to errors associated with antenatal
magnesium sulphate occurring in their obstetric units,
and ensure safety procedures are in place to help pre-
vent such accidents.
It is important, where ever possible, that women receive
a full explanation, not only of why antenatal magnesium
sulphate is in their case needed, but also of the nature
of symptoms that may be experienced during treatment.
An understanding of these benefits, the possible adverseeffects, and the vigilant care and monitoring that will be
received during treatment, may help to decrease or
relieve anxiety during treatment that may otherwise be
caused by unexpected adverse effects. Health professionals
should seek to make their approach to information
provision open and honest.
Implications for research
Fewer maternal adverse effects may be a benefit of lower
dose magnesium sulphate regimens, and whilst this
review did not formally assess effectiveness, no trial
included in this review showed compromised efficacy
with such lower dose regimens. Further trials comparing
different regimens are however required, to determine the
optimal regimens that achieve the desired clinical effect-
iveness with minimal maternal adverse effects and cessa-
tion, for each of the known beneficial indications for
use. Such trials must be of a high quality, and of suffi-
cient sample size to assess the comparative effects on
relevant maternal and/or infant efficacy and safety re-
lated outcomes. For all future randomised trials, consid-
eration of the extension for harms of the CONSORT
statement [15] including during the study design phase,
is crucial to ensure the better collection and reporting
of adverse effects [167].
A number of important questions remain regarding
maternal adverse effects of magnesium sulphate. Com-
mon reasons for ceasing treatment, and how serious
adverse effects and treatment cessation vary according
to total dose of magnesium sulphate received, require
evaluation. Such questions may be addressed in an individ-
ual patient data meta-analysis. Additional well-designed
and sufficiently powered trials or observational studies
are required to address the need to reduce errors associ-
ated with magnesium sulphate administration. Such
studies may, for example, consider comparing the use of
a pre-mixed solution with a concentrate requiring dilu-
tion, or the use of separate infusion bags for the loading
and maintenance dose infusions, compared with the use
of the same infusion bag with the need to reprogram in-
fusion rates.Additional files
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